Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
H.C. Wainwright Upgrades Prelude Therapeutics(PRLD.US) to Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Robert Burns upgrades $Prelude Therapeutics(PRLD.US)$ to a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 28.2%
KIVA SALES LEADER JOINS PRELUDE TO ACCELERATE EXPANSION ACROSS THE CANNABIS SUPPLY CHAIN
Prelude Therapeutics Price Target Maintained With a $7.00/Share by JMP Securities
Prelude Therapeutics (PRLD) Gets a Sell From Barclays
JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Maintains Target Price $7
JMP Securities analyst Reni Benjamin maintains $Prelude Therapeutics(PRLD.US)$ with a buy rating, and maintains the target price at $7.According to TipRanks data, the analyst has a success rate of 33.
Buy Rating Affirmed for Prelude Therapeutics on Promising PRT3789 Trial Results and Strong Financial Position
Prelude Therapeutics: Uncertainties in Drug Efficacy and Dosing Prompt Sell Rating
Prelude Therapeutics Says PRT3789 Shows 'Encouraging Signs' in Phase 1 Trial; Shares Fall
Express News | Prelude Therapeutics Inc - PRT3789 Generally Well-Tolerated With No Dose-Limiting Toxicities
Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
Express News | Prelude Therapeutics’ Smarca2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial
H.C. Wainwright Maintains Prelude Therapeutics(PRLD.US) With Hold Rating, Maintains Target Price $5
H.C. Wainwright analyst Robert Burns maintains $Prelude Therapeutics(PRLD.US)$ with a hold rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 26
Prelude Therapeutics Unveils Promising Cancer Treatment Data at ESMO
Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024
Hold Rating on Prelude Therapeutics Pending Phase 1 Results of PRT3789
HC Wainwright & Co. Reiterates Neutral on Prelude Therapeutics, Maintains $5 Price Target
Prelude Therapeutics Analyst Ratings
UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday
Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $4
Morgan Stanley analyst Jeffrey Hung maintains $Prelude Therapeutics(PRLD.US)$ with a sell rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success rate of 52.